Literature DB >> 31267676

Neurosurgery medical robot Remebot for the treatment of 17 patients with hypertensive intracerebral hemorrhage.

Tao Wang1, Quan-Jun Zhao1, Jian-Wen Gu1, Tie-Jun Shi1, Xujun Yuan2, Jia Wang1, Shao-Jie Cui1.   

Abstract

OBJECTIVE: To verify the minimally invasive surgical approach and therapeutic effects of using the medical neurosurgery robot Remebot to treat hypertensive intracerebral hemorrhage (HICH).
METHODS: Clinical data for 17 HICH patients were analyzed retrospectively. Hematoma evacuation and tube drainage using Remebot frameless stereotaxic techniques were performed for all patients, and urokinase was injected into the hematomas after the operations.
RESULTS: Robot-assisted stereotactic techniques can accurately guide hematoma punctures, and no deaths occurred among these patients. The average positioning error was 1.28 ± 0.49 mm. The average drainage duration was 3.4 days. The 3-month postoperative follow-up revealed improved neurological functions and quality of life for all patients.
CONCLUSIONS: The medical neurosurgery robot Remebot is minimally invasive, has high positional accuracy, and facilitates surgical planning according to the shape of the hematoma. Therefore, robot-assisted surgery using Remebot represents a safe and effective treatment method for hematoma evacuation and tube drainage in HICH patients.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  drainage; frameless stereotaxy; hypertensive; intracranial hemorrhage; robotics

Mesh:

Year:  2019        PMID: 31267676     DOI: 10.1002/rcs.2024

Source DB:  PubMed          Journal:  Int J Med Robot        ISSN: 1478-5951            Impact factor:   2.547


  8 in total

Review 1.  Use of emerging technologies to enhance the treatment paradigm for spontaneous intraventricular hemorrhage.

Authors:  Austin B Carpenter; Jacques Lara-Reyna; Trevor Hardigan; Travis Ladner; Christopher Kellner; Kurt Yaeger
Journal:  Neurosurg Rev       Date:  2021-08-15       Impact factor: 3.042

Review 2.  Minimally Invasive Intracerebral Hemorrhage Evacuation: A review.

Authors:  Mishek J Musa; Austin B Carpenter; Christopher Kellner; Dimitri Sigounas; Isuru Godage; Saikat Sengupta; Chima Oluigbo; Kevin Cleary; Yue Chen
Journal:  Ann Biomed Eng       Date:  2022-02-28       Impact factor: 3.934

3.  The Efficacy of Mannitol Combined with 6-Aminocaproic Acid in the Treatment of Patients with Cerebral Hemorrhage and Its Impact on Immune Function.

Authors:  Buxian Tian; Bohan Tian; Yuhong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-12       Impact factor: 2.650

4.  Effect of Robot-Assisted Neuroendoscopic Hematoma Evacuation Combined Intracranial Pressure Monitoring for the Treatment of Hypertensive Intracerebral Hemorrhage.

Authors:  Shiqiang Wu; Heping Wang; Junwen Wang; Feng Hu; Wei Jiang; Ting Lei; Kai Shu
Journal:  Front Neurol       Date:  2021-12-02       Impact factor: 4.003

5.  Tripartite intensive intervention for prevention of rebleeding in elderly patients with hypertensive cerebral hemorrhage.

Authors:  Cai-Xia Li; Li Li; Jin-Feng Zhang; Qi-Hong Zhang; Xiao-Hong Jin; Guo-Juan Cai
Journal:  World J Clin Cases       Date:  2021-11-26       Impact factor: 1.337

6.  3D-Slicer Software-Assisted Neuroendoscopic Surgery in the Treatment of Hypertensive Cerebral Hemorrhage.

Authors:  Rongfang Liao; Longmao Liu; Bo Song; Xinhong Wan; Shuo Wang; Jianhong Xu
Journal:  Comput Math Methods Med       Date:  2022-02-18       Impact factor: 2.238

7.  A comparative study on the efficacy of robot of stereotactic assistant and frame-assisted stereotactic drilling, drainage for intracerebral hematoma in patients with hypertensive intracerebral hemorrhage.

Authors:  Liang Liang; Xin Li; Haiqing Dong; Xin Gong; Guanpeng Wang
Journal:  Pak J Med Sci       Date:  2022 Sep-Oct       Impact factor: 2.340

Review 8.  Minimally Invasive Surgery for Intracerebral and Intraventricular Hemorrhage.

Authors:  Zelong Zheng; Qi Wang; Shujie Sun; Jinbiao Luo
Journal:  Front Neurol       Date:  2022-02-22       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.